- Home
- WAVE vs PRLD Comparison
WAVE vs PRLD Comparison
Compare WAVE & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- PRLD
- Stock Information
- Founded
- WAVE 2011
- PRLD 2016
- Country
- WAVE Israel
- PRLD United States
- Employees
- WAVE N/A
- PRLD N/A
- Industry
- WAVE Electric Utilities: Central
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- WAVE Utilities
- PRLD Health Care
- Exchange
- WAVE Nasdaq
- PRLD Nasdaq
- Market Cap
- WAVE 64.4M
- PRLD 73.7M
- IPO Year
- WAVE 2021
- PRLD 2020
- Fundamental
- Price
- WAVE $10.37
- PRLD $1.05
- Analyst Decision
- WAVE
- PRLD Strong Buy
- Analyst Count
- WAVE 0
- PRLD 2
- Target Price
- WAVE N/A
- PRLD $4.50
- AVG Volume (30 Days)
- WAVE 83.1K
- PRLD 611.2K
- Earning Date
- WAVE 11-21-2024
- PRLD 02-13-2025
- Dividend Yield
- WAVE N/A
- PRLD N/A
- EPS Growth
- WAVE N/A
- PRLD N/A
- EPS
- WAVE N/A
- PRLD N/A
- Revenue
- WAVE $279,000.00
- PRLD $3,000,000.00
- Revenue This Year
- WAVE N/A
- PRLD N/A
- Revenue Next Year
- WAVE N/A
- PRLD N/A
- P/E Ratio
- WAVE N/A
- PRLD N/A
- Revenue Growth
- WAVE 933.33
- PRLD N/A
- 52 Week Low
- WAVE $1.01
- PRLD $0.80
- 52 Week High
- WAVE $17.63
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- WAVE 46.80
- PRLD 45.27
- Support Level
- WAVE $8.00
- PRLD $0.98
- Resistance Level
- WAVE $11.46
- PRLD $1.43
- Average True Range (ATR)
- WAVE 1.43
- PRLD 0.12
- MACD
- WAVE -0.21
- PRLD -0.02
- Stochastic Oscillator
- WAVE 38.54
- PRLD 14.14
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.